Guanidine Hydrochloride

(Metaiodobenzylguanidine (MIBG))

PreclinicalSmall molecule

Merck & Co.

Guanidine Hydrochloride is one of 4 small molecule programs targeting Ablation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

AblationCompleted

AblationPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Ablation

#DrugCompanyPhaseTrials

Stadol

Bristol-Myers Squibb

Preclinical

1 2

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 3

Guanidine Hydrochloride

Merck & Co.

Preclinical

1 4

Ajmaline

UUniversitair Ziekenhuis Brussel

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Neuroblastoma2 trials

High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

Completed·UUniversity of California, San Francisco·Phase 1·NCT01313936·32 enrolled

131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol

Available·KKieuhoa Vo··NCT01370330

Neuroendocrine Tumors1 trial

Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT04510311·32 enrolled

Ablation1 trial

Imaging With a Radio Tracer to Guide VT Ablations

Completed·UUniversity of Maryland, Baltimore·N/A·NCT01250912·20 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

GUANIDINE HYDROCHLORIDE

NDA NDA001546

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Metaiodobenzylguanidine (MIBG). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Metaiodobenzylguanidine (MIBG) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Metaiodobenzylguanidine (MIBG). EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA001546). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Merck & Co.

Guanidine Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Neuroblastoma2 trials

Neuroendocrine Tumors1 trial

Ablation1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News